Preclinical proof of concept for VivoVec, a lentiviral-based platform for in vivo CAR T-cell engineering

BACKGROUND: Chimeric antigen receptor (CAR) T-cell therapies have demonstrated transformational outcomes in the treatment of B-cell malignancies, but their widespread use is hindered by technical and logistical challenges associated with ex vivo cell manufacturing. To overcome these challenges, we d...

Descripción completa

Detalles Bibliográficos
Autores principales: Michels, Kathryn R, Sheih, Alyssa, Hernandez, Susana A, Brandes, Alissa H, Parrilla, Don, Irwin, Blythe, Perez, Anai M, Ting, Hung-An, Nicolai, Christopher J, Gervascio, Timothy, Shin, Seungjin, Pankau, Mark D, Muhonen, Mason, Freeman, Jessica, Gould, Sarah, Getto, Rich, Larson, Ryan P, Ryu, Byoung Y, Scharenberg, Andrew M, Sullivan, Alessandra M, Green, Shon
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2023
Materias:
Immune Cell Therapies and Immune Cell Engineering
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10016276/
https://www.ncbi.nlm.nih.gov/pubmed/36918221
http://dx.doi.org/10.1136/jitc-2022-006292

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10016276/
https://www.ncbi.nlm.nih.gov/pubmed/36918221
http://dx.doi.org/10.1136/jitc-2022-006292

Ejemplares similares